Roche granted FDA’s Orphan Drug status for pralsetinib in solid tumors

Feb. 22, 2022 3:15 PM ETRoche Holding AG (RHHBY), RHHBF, BPMCBy: Dulan Lokuwithana, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • The U.S. Food and Drug Administration (FDA) has awarded Genentech, the U.S.-based unit of Swiss pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF), the Orphan Drug Designation for pralsetinib in the treatment of certain types of solid

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.